Question special

Hello everyone! Thank you to the authors and experts for participating in this lively discussion.

The article by Dr. Quinn et al mentions that PD-L1 expression did not delineate the patients who were more likely to benefit from nivolumab and this was also seen in the study by Dr. Motzer et al as patients with a PD-L1 expression of less than 1% experienced a higher OS than patients with a PD-L1 expression of greater than 1%. Do the authors and experts have any thoughts on why this might be the case in RCC, as opposed to the outcomes seen with studies on metastatic melanoma and some types of lung cancer?

As a follow up question, are there ways to identify RCC patients that may experience a greater response to nivolumab, such as is seen with testing KRAS for the efficacy of cetuximab in metastatic colorectal carcinoma?